FILE – In this Dec. 15, 2020, file photo, a droplet falls from a syringe after a person was injected with the Pfizer COVID-19 vaccine at a hospital in Providence, R.I. (AP Photo/David Goldman, File)
OAN Newsroom
UPDATED 11:55 AM PT – Monday, September 20, 2021
According to Pfizer, recent clinical trials show their COVID-19 vaccine is ”safe” and creates strong antibodies in children aged five to 11-year-olds. In a highly-anticipated press release Monday, the medical research company said it would seek FDA emergency use authorization for the vaccine’s in children by the end of the month.
Pfizer said they used a third of the full size dosage for their clinical trials with children and reportedly saw antibodies just as strong as those found in fully vaccinated adults.
“We measure the ability of antibody from the children that were vaccinated to kill the virus and how well that matched up the antibody from 16 to 25-year-olds,” explained Dr. Bill Gruber, Pfizer Senior Vice President. “And it matched very closely.”
Today with @BioNTech_Group, we are proud to announce positive topline results from the pivotal trial of our #COVID19 vaccine in children 5-11 years of age. https://t.co/a1mSEgxNHQ pic.twitter.com/9xGfYEzFuy
— Pfizer Inc. (@pfizer) September 20, 2021
This comes as critics argue more data is needed to support the group’s findings.
MORE NEWS: Nunez On Biden Reducing Fla. Monoclonal Supply: ‘Politics At Its Worst, Disgusting’
Be the first to comment